StockData
Sangamo Therapeutics, Inc logo

Sangamo Therapeutics, Inc (SGMOQ) stock

SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)

Close on Oct 19, 2026Market cap $39.43MP/E –Yield –

Sangamo Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Sangamo Therapeutics's R&D Expenses for the twelve months ending Mar 31, 2026 was $113.23M, up 11.4% year over year. For fiscal 2025 it was $112.67M, up 1.0% from the year before. Over ten years it grew 5.3% a year on average. The highest annual figure on record is $249.90M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$112.67M+1.0%
FY2024Dec 31, 2024$111.52M-52.4%
FY2023Dec 31, 2023$234.06M-6.3%
FY2022Dec 31, 2022$249.90M+8.3%
FY2021Dec 31, 2021$230.82M+27.8%
FY2020Dec 31, 2020$180.65M+23.8%
FY2019Dec 31, 2019$145.92M+27.0%
FY2018Dec 31, 2018$114.87M+74.8%
FY2017Dec 31, 2017$65.73M+0.2%
FY2016Dec 31, 2016$65.62M-2.4%
FY2015Dec 31, 2015$67.20M+17.9%
FY2014Dec 31, 2014$56.97M+53.8%
FY2013Dec 31, 2013$37.04M+16.8%
FY2012Dec 31, 2012$31.71M-1.2%
FY2011Dec 31, 2011$32.10M-3.2%
FY2010Dec 31, 2010$33.15M+14.4%
FY2009Dec 31, 2009$28.98M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026$26.57M+2.2%
Q4 FY2025Dec 31, 2025$31.44M+32.8%
Q3 FY2025Sep 30, 2025$28.14M+1.5%
Q2 FY2025Jun 30, 2025$27.08M+11.8%
Q1 FY2025Mar 31, 2025$26.01M-27.5%
Q4 FY2024Dec 31, 2024$23.68M-53.3%
Q3 FY2024Sep 30, 2024$27.73M-51.4%
Q2 FY2024Jun 30, 2024$24.22M-61.6%
Q1 FY2024Mar 31, 2024$35.89M-43.2%
Q4 FY2023Dec 31, 2023$50.71M-23.4%
Q3 FY2023Sep 30, 2023$57.09M-12.3%
Q2 FY2023Jun 30, 2023$63.05M+5.0%
Q1 FY2023Mar 31, 2023$63.22M+7.9%
Q4 FY2022Dec 31, 2022$66.18M+27.8%
Q3 FY2022Sep 30, 2022$65.12M+4.2%
Q2 FY2022Jun 30, 2022$60.02M-0.1%
Q1 FY2022Mar 31, 2022$58.58M+3.8%
Q4 FY2021Dec 31, 2021$51.80M-1.1%
Q3 FY2021Sep 30, 2021$62.50M+38.0%
Q2 FY2021Jun 30, 2021$60.09M+44.7%
Q1 FY2021Mar 31, 2021$56.43M+36.1%
Q4 FY2020Dec 31, 2020$52.36M+36.6%
Q3 FY2020Sep 30, 2020$45.29M+24.8%
Q2 FY2020Jun 30, 2020$41.52M+13.9%
Q1 FY2020Mar 31, 2020$41.48M+19.0%
Q4 FY2019Dec 31, 2019$38.33M+15.3%
Q3 FY2019Sep 30, 2019$36.29M+26.0%
Q2 FY2019Jun 30, 2019$36.46M+24.6%
Q1 FY2019Mar 31, 2019$34.85M+48.0%
Q4 FY2018Dec 31, 2018$33.25M+71.6%
Q3 FY2018Sep 30, 2018$28.81M+56.4%
Q2 FY2018Jun 30, 2018$29.26M+95.2%
Q1 FY2018Mar 31, 2018$23.55M+81.9%
Q4 FY2017Dec 31, 2017$19.38M+39.5%
Q3 FY2017Sep 30, 2017$18.43M+8.3%
Q2 FY2017Jun 30, 2017$14.98M-23.0%
Q1 FY2017Mar 31, 2017$12.94M–
Q4 FY2016Dec 31, 2016$13.89M–
Q3 FY2016Sep 30, 2016$17.01M–
Q2 FY2016Jun 30, 2016$19.45M–

More Sangamo Therapeutics figures

See a number that looks wrong?